# Sweden Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Sweden HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Sweden (SWE)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $9.4B
- Products: 42
- Buyer markets: 25
- Average CAGR: +17.5%
- Global sector size: $776.4B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $289.9B | $4.7B | $104.2B | +6.6% | 17 | +2.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $161.5B | $2.1B | $63.6B | +64.8% | 15 | +1.1% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $29.9B | $74.3M | $47.8B | +29.5% | 4 | +0.4% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $28.6B | $307.9M | $32.7B | +49.3% | 4 | +1.8% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $9.5M | $23.0B | -4.5% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $25.9B | $3.0M | $21.6B | +13.3% | 5 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $15.4B | $27.4K | $15.5B | -12.2% | 2 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $24.4B | $85.2M | $14.6B | -0.8% | 7 | +0.3% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $19.9B | $99.7M | $13.6B | +10.4% | 5 | +0.4% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $26.4B | $1.3B | $13.2B | +29.1% | 5 | +3.9% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $13.4B | $4.4M | $12.3B | +9.3% | 5 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $6.8B | $238.1K | $9.6B | +6.0% | 2 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $5.7B | $2.2M | $8.2B | +62.8% | 4 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $18.5M | $7.4B | +7.3% | 2 | +0.2% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $600.3 | $6.7B | -31.6% | 1 | +0.0% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $10.1B | $40.5K | $6.4B | +0.7% | 3 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $113.0M | $5.7B | +33.9% | 2 | +1.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $5.2K | $4.8B | +5.4% | 1 | +0.0% |
| HS 282200 - Cobalt oxides and hydroxides: commercial cobalt oxides | $2.4B | $20.7K | $4.6B | +11.5% | 1 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $8.9B | $157.4M | $4.4B | +13.8% | 2 | +1.8% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $3.6B | $1.8M | $4.4B | -11.2% | 2 | +3.6% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $1.4M | $4.1B | +9.5% | 2 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $2.0B | $7.5 | $3.8B | -25.7% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $427.5M | $3.2B | +46.1% | 2 | +6.9% |
| HS 282520 - Lithium oxide and hydroxide | $1.6B | $194.8 | $2.7B | +0.3% | 1 | +0.0% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $7.1M | $2.4B | -19.8% | 1 | +0.3% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $7.9 | $2.4B | -50.5% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $1.0 | $2.4B | -34.9% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.4B | $70.1K | $2.3B | +11.0% | 1 | +0.0% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $1.4K | $2.2B | -11.2% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.0B | $198.0K | $2.0B | +24.5% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $2.2M | $2.0B | +14.3% | 1 | +0.1% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $486.6K | $2.0B | +7.8% | 1 | +0.0% |
| HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $17.3K | $1.9B | +8.4% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $20.2K | $1.9B | +8.7% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $266.8 | $1.8B | -9.7% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $599.1 | $1.8B | -4.2% | 1 | +0.0% |
| HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $4.9B | $183.1K | $1.7B | -13.6% | 1 | +0.0% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $40.6K | $1.7B | -0.7% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $28.2K | $1.4B | -8.6% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $30.1 | $1.4B | -19.6% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $220.0K | $1.4B | +21.7% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $150.1B calculated opportunity across 20 products.
- China (CHN): $41.7B calculated opportunity across 15 products.
- Germany (DEU): $38.5B calculated opportunity across 13 products.
- Slovenia (SVN): $37.4B calculated opportunity across 5 products.
- Switzerland, Liechtenstein (CHE): $36.4B calculated opportunity across 4 products.
- Belgium (BEL): $29.4B calculated opportunity across 5 products.
- Italy (ITA): $23.3B calculated opportunity across 4 products.
- Netherlands (NLD): $19.3B calculated opportunity across 5 products.
- Canada (CAN): $11.7B calculated opportunity across 6 products.
- Republic of Korea (KOR): $10.9B calculated opportunity across 5 products.
- United Kingdom (GBR): $10.8B calculated opportunity across 5 products.
- Japan (JPN): $8.5B calculated opportunity across 3 products.

## Growth stars

- HS 300215: +64.8% average CAGR, $63.6B calculated opportunity.
- HS 284190: +62.8% average CAGR, $8.2B calculated opportunity.
- HS 300214: +49.3% average CAGR, $32.7B calculated opportunity.
- HS 381512: +46.1% average CAGR, $3.2B calculated opportunity.
- HS 330499: +33.9% average CAGR, $5.7B calculated opportunity.
- HS 293719: +29.5% average CAGR, $47.8B calculated opportunity.
- HS 300212: +29.1% average CAGR, $13.2B calculated opportunity.
- HS 381800: +24.5% average CAGR, $2.0B calculated opportunity.
- HS 340220: +21.7% average CAGR, $1.4B calculated opportunity.
- HS 300420: +14.3% average CAGR, $2.0B calculated opportunity.

## Diversification opportunities

- HS 300490: 17 buyer markets, $104.2B calculated opportunity.
- HS 300215: 15 buyer markets, $63.6B calculated opportunity.
- HS 300439: 7 buyer markets, $14.6B calculated opportunity.
- HS 300220: 5 buyer markets, $21.6B calculated opportunity.
- HS 382499: 5 buyer markets, $13.6B calculated opportunity.
- HS 300212: 5 buyer markets, $13.2B calculated opportunity.
- HS 382600: 5 buyer markets, $12.3B calculated opportunity.
- HS 293719: 4 buyer markets, $47.8B calculated opportunity.
- HS 300214: 4 buyer markets, $32.7B calculated opportunity.
- HS 284190: 4 buyer markets, $8.2B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.